Join millions of truth-seekers and receive exclusive uncensored facts about the 2020/2021 COVID-19 chaos and the Great Reset.

Discover the Truth About the COVID-19 / "Great Reset" One Button At a Time

Who Is Vivek Ramaswamy?

Vivek Ramaswamy | Who Is Vivek Ramaswamy? Facts You Need to Know! Why Did Ramaswamy’s Roivant & Pfizer Team Up to Unveil Priovant Therapeutics? Why Did Ramaswamy’s Roivant List Subsidiary Companies In China As Recently As February 2022?

Vivek Ramaswamy is listed on the Paul (brother of George Soros) & Daisy Soros Fellowships for New Americans website. Vivek Ramaswamy’s voting record shows that he is not a registered Republican as of August of 2023 and he donated to Anti-Trump democrat candidates in 2016. At the age of 29, Ramaswamy started Roivant Sciences in 2014. In 2021, Roivant grew its computational drug discovery engine with the acquisition of Silicon Therapeutics, Silicon Therapeautics provides physics-based approaches at to be integrated with machine learning-based approaches at VantAI. In 2022 Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases. In 2020 Ramaswamy posted on his Twitter account: “Wearing a Mask = Personal Responsibility. It’s Puzzling When Conservatives Oppose It.”

Who Is Vivek Ramaswamy (Born August 9th 1985)?

Age 37, Vivek Ramaswamy, in 2014, Ramaswamy founded the biopharmaceutical company Roivant Sciences after working as an investment partner at a hedge fund. After stepping down as Roivant’s chief executive in 2021, Ramaswamy co-founded and has served as executive chairman of Strive Asset Management, an investment firm countering traditional emphasis on corporate social responsibility. In February 2023, Ramaswamy declared his candidacy for the Republican Party’s nomination for president in the 2024 election.

Vivek Ramaswamy | How Did Vivek Ramaswamy Become a Billionaire? + 19 Facts You Need to Know! Why Did Ramaswamy’s Roivant & Pfizer Team Up to Unveil Priovant Therapeutics? (See the Video Description for All Supporting FACTS)

FACT #22 – “Vivek Ramaswamy Is the Guy Who Funded Arbutus & Acuitas. So We Have a Republican Candidate for President Who Is Using for His Campaign Money He Made On His Interest In Every Shot That Was Delivered.” – Dr. David Martin

Roivant Makes $116 Million Investment In Arbutus, Backing Battle With Moderna

READ – https://www.forbes.com/sites/nathanvardi/2017/10/02/roivant-makes-116-million-investment-in-arbutus-backing-battle-with-moderna/?sh=148946905e20

FACT #21 – 2023 (Age 38) Roivant Loses Copious Amounts of Money Year After Year | Virtually All of Ramaswamy’s Companies Consistently Lose Money And None Have Ever Turned a Profit Consistently

2023 – Roivant Is Predicted to Lose Another $1.03 Billion According to Bloomberg / Fortune – https://fortune.com/2023/06/14/vivek-ramaswamy-is-threatening-gop-heavyweights-in-the-polls-but-his-business-record-doesnt-live-up-to-the-hype/
2022 – Roivant Lost $1.12 Billion In 2022
2021 – Roivant Lost $698 Million In 2021
2020 – Roivant Lost $433 Million In 2020

FACT #20 – 2023 – (Age 38) Roivant Set Up a New Subsidiary, Telavant, to Advance the Asset. Pfizer Owns 25% of Telavant and retains the rights to RVT-3101 outside of the U.S. and Japan. According to the WSJ, Roche is nearing a deal to buy Roivant’s rights to the molecule

READ – https://www.fiercebiotech.com/biotech/roche-lining-7b-roivant-deal-join-merck-co-bowel-disease-race-wsj#:~:text=Roivant%20set%20up%20a%20new,Roivant’s%20rights%20to%20the%20molecule.

FACT #19 – 2023 – (Age 38) Vivek Ramaswamy’s Pharmacy Firm to Sell Experimental Drug In $7B Deal –

READ – https://nypost.com/2023/07/14/vivek-ramaswamy-founded-company-to-sell-drug-in-7b-deal/

FACT #18 – 2022 (June 28) – (Age 37) Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus

READ – https://www.pfizer.com/news/press-release/press-release-detail/roivant-and-pfizer-unveil-priovant-therapeutics-and-ongoing

FACT #17 – 2022 – (Age 37) As Recently As February 2022, Ramaswamy’s Roivant Listed Subsidiary Companies In China, According to SEC Filings:-

READ – https://www.dossier.today/p/vetting-vivek-ramaswamy?utm_source=%2Fsearch%2Framaswamy&utm_medium=reader2

FACT #16 – 2022 – (Age 37) Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases

READ – https://www.pfizer.com/news/press-release/press-release-detail/roivant-and-pfizer-form-new-vant-company-focused-developing

FACT #15 – 2021 – (Age 36) Roivant Grows Computational Drug Discovery Engine with Acquisition of Silicon Therapeutics | Silicon Therapeautics provides physics-based approaches at to be integrated with machine learning-based approaches at VantAI

READ – https://www.businesswire.com/news/home/20210226005291/en/Roivant-Grows-Computational-Drug-Discovery-Engine-with-Acquisition-of-Silicon-Therapeutics

FACT #14 – (May 3rd) (Age 36) – (Vivek Put an Estimated $950 Million In the Bank While Achieving a Billion Dollar Net Worth from Having Taken Roivant Public)

READ – https://www.reuters.com/legal/transactional/biotech-firm-roivant-sciences-go-public-via-73-bln-spac-deal-2021-05-28/

FACT #13 – 2021 – (February 24) (Age 36) – “To State the Obvious: We Should Aim to Safely Vaccinate Everyone Who Is Eligible.” – Vivek Ramaswamy

READ – https://twitter.com/VivekGRamaswamy/status/1364834169369415686?s=20

FACT #12 – 2020 – (November 9, 2020) (Age 35) – Ramaswamy’s Datavant Sought to Create a Universal Database for Governments That Displays “Every Patient Who Has Been Tested for COVID-19.” – Ramaswamy Wanted to “Fight COVID-19” by Manufacturing a “Single Repository of All the Real-World Medical Data” Thanks to the Production of a “National Data Infrastructure” of Private and Public Patient Records, All Without the Consent of the Actual Patients. Ramaswamy’s Datavant Sought to Profit Off of the Hysteria And Violate Basic Ethical Standards In the Process. Datavant Succeeded In Establishing a Partnership with the National Institutes of Health (NIH).

READ – https://datavant.com/about/news-press/regenstrief-indiana-ctsi-datavant-partner-on-nih-national-covid-19-data-effort/

FACT #11 – 2020 – (July 9th 2020) (Age 35) “Wearing a Mask = Personal Responsibility. It’s Puzzling When Conservatives Oppose It.”

READ – https://twitter.com/VivekGRamaswamy/status/1281108171105333248?s=20

FACT #10 – 2018 – (Age 33) Vivek Ramaswamy Strikes Again, This Time Launching a Beijing-Based Biotech Player with a Pipeline. Before Going Public, Ramaswamy And Roivant Moved Aggressively Into the Chinese Biotech Market and Co-Founded Soivant In 2018

READ – https://endpts.com/vivek-ramaswamy-strikes-again-this-time-launching-a-beijing-based-biotech-player-with-a-pipeline/

FACT #9 – 2018 – (Age 33) Vivek Ramaswamy’s Roivant and Artubus Pooled Their Resources to Create an RNA-Focused Biotech Genevant.

READ – https://www.fiercebiotech.com/biotech/roivant-arbutus-set-up-rna-jv-put-ex-ariad-roche-execs-leadership-posts

Arbutus files patent lawsuit against Pfizer/BioNTech over COVID vaccines

READ – https://www.reuters.com/legal/arbutus-files-patent-infringement-lawsuit-against-pfizerbiontech-2023-04-04/

FACT #8 – 2016 – (Age 31) Vivek Ramaswamy’s Voting Record Shows He is Not a Registered Republican, and Donated to Anti-Trump Democrat Candidate in 2016.

READ – https://www.thegatewaypundit.com/2023/08/vivek-ramaswamys-voting-records-show-he-is-not/

FACT #7 – 2015 – In 2015, He Founded Roivant Subsidiary Axovant. Its Prized Asset Was an Alzheimer’s Drug, Intepirdine, Which Vivek Purchased for $5 Million. However, It Turned Out to be Disappointing When It Failed a Clinical Trial Two Years Later. When Axovant Joined the New York Stock Exchange, Vivek Reported More Than $38 Million, Most of Which Was From Capital Gains, on His Tax Return. In 2020, the Company Was Rebranded as Sio Gene Therapies and is Now Worth $30 Million.

READ – https://www.the-sun.com/news/8898691/vivek-ramaswamy-parents/

FACT #6 – 2015 – (Age 30) Vivek Ramaswamy Said During a CNBC Interview, “The thing with RVT-101, it’s actually a neurotransmitter targeted therapy that actually in part works through the release of acetylcholine.” Acetylcholine (ACh) is an Important Neurotransmitter that Plays a Role in Brain Functions, Such as Memory, and Body Functions, Such as Muscle Contractions to Move Your Muscles. Low Levels of Acetylcholine Are Associated With Memory Issues and Muscle Disorders.

WATCH – https://www.youtube.com/watch?v=75MY4Rr47WM

FACT #5 – In 2014, Vivek Established Roivant Sciences, Based in Bermuda, with Nearly $100 Million in Funding from Various Investors, Including His Former Employer, the Hedge Fund QVT.

READ – https://nypost.com/2023/07/14/vivek-ramaswamy-founded-company-to-sell-drug-in-7b-deal/

FACT #4 – 2013 – (Age 28) Vivek Stated in 2013 That He Had a Net Worth of Around $15 Million Before Graduating from Law School.

READ – https://www.the-sun.com/news/8898691/vivek-ramaswamy-parents/

A huge part of Ramaswamy’s self-created origin story is how he built a successful business when he was still an undergraduate in college, a database called StudentBusinesses.com, and supposedly sold out for millions to the Kaufman Foundation in 2009. He has sat for countless fawning interviews across print media, television, and podcasts focused on his earliest business triumph.

However, Ramaswamy’s 2009 tax returns show realized capital gains of only $37,000, hardly a lucrative exit. The following year, in 2010, Ramaswamy reported zero in capital gains.
READ – https://fortune.com/2023/06/14/vivek-ramaswamy-is-threatening-gop-heavyweights-in-the-polls-but-his-business-record-doesnt-live-up-to-the-hype/

FACT #3 – 2011 – (Age 26) Ramaswamy Received the Paul & Daisy Soros Fellowship for New Americans

READ – https://www.forbes.com/sites/mattnovak/2023/05/03/wikipedia-editor-says-they-were-paid-to-change-vivek-ramaswamys-page/?sh=6bf132fc51a3

FACT #2 – 2011 – (Age 26) Why Is Vivek Ramaswamy Listed On the Paul & Daisy Soros Fellowships for New Americans Website? George Soro’s Brother (Often Known As “The Invisible Soros”)

READ – https://www.pdsoros.org/meet-the-fellows/vivek-ramaswamy

FACT #1 – 2007 – (Age 22) – Why Did Vivek Ramaswamy Advocate for the Creation of Human-Animal Chimeras While At Harvard? (Which Was Published In the Boston Globe and The New York Times). Why was Vivek Ramaswamy’s Thesis On the Need to Ethically Produce Human-Animal Chimeras (Hybrids) for Medical Experimentation?